Contemporary management of patients with left ventricular systolic dysfunction; Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry

European Heart Journal

Volumn 20, Issue 16, 1999, Pages 1182-1190

  Bart, B A ^a,l   Ertl, G ^b   Held, P ^c   Kuch, J ^d   Maggioni, A P ^e   McMurray, J ^f   Michelson, E L ^m   Rouleau, J L ^g   Warner Stevenson, L ^h   Swedberg, K ⁱ   Young, J B ^j   Yusuf, S ^k   Sellers, M A ^a   Granger, C B ^a   Califf, R M ^a   Pfeffer, M A ^h  

^a DUKE UNIVERSITY   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Astra Hassle   (Sweden)

^d MEDICAL UNIVERSITY OF WARSAW   (Poland)

^e GISSI Group   (Italy)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

^g MONTREAL HEART INSTITUTE   (Canada)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ UNIVERSITY OF GOTHENBURG   (Sweden)

^j LERNER RESEARCH INSTITUTE   (United States)

^k MCMASTER UNIVERSITY   (Canada)

^l HENNEPIN COUNTY MEDICAL CENTER   (United States)

^m NONE

more..

Author keywords

ACE inhibitor; Heart failure; Management; Medication usage

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; DEMOGRAPHY; DRUG HYPERSENSITIVITY; DRUG USE; EUROPE; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; PRIORITY JOURNAL; REGISTER; RETROSPECTIVE STUDY;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DRUG UTILIZATION REVIEW; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; SYSTOLE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0032807953     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1998.1481     Document Type: Article

References (50)

1. Anonymous. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987; 316: 1429-35.
2. Anonymous. Heart failure: management of patients with left-ventricular systolic dysfunction. Agency for Health Care Policy and Research. Clinical Practice Guideline - Quick Reference Guide for Clinicians 1994: 1-25.
3. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials [published erratum appears in JAMA 1995 Aug 9; 274(6): 462. JAMA 1995; 273: 1450-6.
4. Cohn JN. The management of chronic heart failure. N Engl J Med 1996; 335: 490-8.
5. Clarke KW, Gray D, Hamptom JR. Evidence of inadequate investigation and treatment of patients with heart failure. Br Heart J 1994; 71: 584-7.
6. Stevenson WG, Stevenson LW, Middlekauff HR et al. Improving survival for patients with advanced heart failure: a study of 737 consecutive patients. J Am Coll Cardiol 1995; 26: 1417-23.
7. Bart BA, Gattis WA, Diem SJ, O'Connor CM. Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction. Am J Cardiol 1997; 79: 1118-20.
8. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995; 333: 1190-5.
9. Philbin EF, Andreaou C, Rocco TA, Lynch LJ, Baker SL. Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. Am J Cardiol 1996; 77: 832-8.
10. Anonymous. Mortality risk and patterns of practice in 4606 acute care patients with congestive heart failure. The relative importance of age, sex, and medical therapy. Clinical Quality Improvement Network Investigators. Arch Intern Med 1996; 156: 1669-73.
11. Anonymous. Heart failure treatment with angiotensin-converting enzyme inhibitors in hospitalized Medicare patients in 10 large states. The Large State Peer Review Organization Consortium. Arch Intern Med 1997; 157: 1103-8.
12. Stafford RS, Saglam D, Blumenthal D. National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure. Arch Intern Med 1997; 157: 2460-4.
13. Anonymous. Survey on heart failure in Italian hospital cardiology units: Results from the SEOSI study. Eur Heart J 1997; 18: 1457-64.
14. Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 1992; 20: 301-6.
15. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993; 88: 107-15.
16. Rodeheffer RJ, Jacobsen SJ, Gersh BJ et al. The incidence and prevalence of congestive heart failure in Rochester, Minnesota. Mayo Clinic Proceedings 1993; 68: 1143-50.
17. Krumholz HM, Parent EM, Tu N et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med 1997; 157: 99-104.
18. Reis SE, Holubkov R, Edmundowicz D et al. Treatment of patients admitted to the hospital with congestive heart failure: specialty-related disparities in practice patterns and outcomes. J Am Coll Cardiol 1997; 30: 733-8.
19. Oka RK, Fortmann SP, Varady AN. Differences in treatment of acute myocardial infarction by sex, age, and other factors (the Stanford Five-City Project). Am J Cardiol 1996; 78: 861-5.
20. Steingart RM, Packer M, Hamm P et al. Sex differences in the management of coronary artery disease. Survival and Ventricular Enlargement Investigators. N Engl J Med 1991; 325: 226-30.
21. Ayanian JZ, Epstein AM. Differences in the use of procedures between women and men hospitalized for coronary heart disease. N Engl J Med 1991; 325: 221-5.
22. Pilote L, Califf RM, Sapp S et al. Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. N Engl J Med 1995; 333: 565-72.
23. Eisenberg MJ, Califf RM, Cohen EA, Adelman AG, Mark DB, Topol EJ. Use of evidence-based medical therapy in patients undergoing percutaneous coronary revascularization in the United States, Europe, and Canada. Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I) and Canadian Coronary Atherectomy Trial (CCAT) investigators. Am J Cardiol 1997; 79: 867-72.
24. Hillis GS, Al-Mohammad A, Wood M, Jennings KP. Changing patterns of investigation and treatment of cardiac failure in hospital. Heart 1996; 76: 427-9.
25. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669-77.
26. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992; 117: 234-42.
27. Kostis JB, Shelton BJ, Yusuf S et al. Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the Studies of Left Ventricular Dysfunction. Am Heart J 1994; 128: 358-64.
28. Kostis JB, Shelton B, Gosselin G et al. Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. Am Heart J 1996; 131: 350-5.
29. Packer M, O'Connor CM, Ghali JK et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996; 335: 1107-14.
30. Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-55.
31. Anonymous. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325: 293-302.
32. Anonymous. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997; 336: 525-33.
33. Loeb HS, Johnson G, Henrick A et al. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993; 87: VI78-87.
34. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 1994; 344: 493-8.
35. Wei JY. Age and the cardiovascular system. N Engl J Med 1992; 327: 1735-9.
36. Luchi RJ, Snow E, Luchi JM, Nelson CL, Pircher FJ. Left ventricular function in hospitalized geriatric patients. J Am Ger Soc 1982; 30: 700-5.
37. Bart BA, Shaw LK, McCants CBJ, Fortin DF, Lee KL, Califf RM. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol 1997; 30: 1002-8.
38. Lindenfeld J, Krause-Steinrauf H, Salerno J. Where are all the women with heart failure? J Am Coll Cardiol 1997; 30: 1417-9.
39. Bourassa M, Gurne O, Bangdiwala S. Natural history and patterns of current practice in heart failure. The Studies of Left Ventricular Dysfunction (SOLVD) Investigators. J Am Coll Cardiol 1993; 22: 14A-29A.
40. Bangdiwala SI, Weiner DH, Bourassa MG, Friesinger GCd, Ghali JK, Yusuf S. Studies of Left Ventricular Dysfunction (SOLVD) Registry: rationale, design, methods and description of baseline characteristics. Am J Cardiol 1992; 70: 347-53.
41. Young JB, Weiner DH, Yusuf S et al. Patterns of medication use in patients with heart failure: a report from the Registry of Studies of Left Ventricular Dysfunction (SOLVD). South Med J 1995; 88: 514-23.
42. Pfeffer MA, Stevenson LW. Beta-adrenergic blockers and survival in heart failure [editorial; comment]. N Engl J Med 1996; 334: 1396-7.
43. Doughty RN, Rodgers A, Sharpe N, MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. Eur Heart J 1997; 18: 560-5.
44. Epstein AE, Hallstrom AP, Rogers WJ et al. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST). JAMA 1993; 270: 2451-5.
45. Anonymous. The effect of diltiazem on mortality and reinfarction after myocardial infarction. The Multicenter Diltiazem Postinfarction Trial Research Group. N Engl J Med 1988; 319: 385-92.
46. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-31.
47. Lamas GA, Pfeffer MA, Hamm P, Wertheimer J, Rouleau JL, Braunwald E. Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators. N Engl J Med 1992; 327: 241-7.
48. Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: Rationale for preventive strategies and comprehensive disease management. Am Heart J 1997; 133: 703-12.
49. Anonymous. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). J Am Coll Cardiol 1995; 26: 1376-98.
50. Anonymous. The treatment of heart failure. Task Force of the Working Group on Heart Failure of the European Society of Cardiology. Eur Heart J 1997; 18: 736-53.